Amneal Pharmaceuticals, Inc.AMRXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P0
Near historical low
vs 5Y Ago
-2x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -45.04% |
| Q3 2025 | 26.75% |
| Q2 2025 | 19.55% |
| Q1 2025 | -25.50% |
| Q4 2024 | -8.15% |
| Q3 2024 | 64.70% |
| Q2 2024 | -5.60% |
| Q1 2024 | -15.60% |
| Q4 2023 | 10.18% |
| Q3 2023 | 9.43% |
| Q2 2023 | -4.25% |
| Q1 2023 | -6.78% |
| Q4 2022 | -16.22% |
| Q3 2022 | 0.15% |
| Q2 2022 | -3.72% |
| Q1 2022 | 1.03% |
| Q4 2021 | 4.87% |
| Q3 2021 | -6.78% |
| Q2 2021 | 4.76% |
| Q1 2021 | -9.44% |
| Q4 2020 | 22.52% |
| Q3 2020 | -5.03% |
| Q2 2020 | 30.47% |
| Q1 2020 | -29.00% |
| Q4 2019 | 30.25% |
| Q3 2019 | -19.43% |
| Q2 2019 | -12.92% |
| Q1 2019 | -4.15% |
| Q4 2018 | 27.71% |
| Q3 2018 | -12.84% |
| Q2 2018 | 11.47% |
| Q1 2018 | 5.54% |
| Q4 2017 | -3.73% |
| Q3 2017 | -7.86% |
| Q2 2017 | 32.20% |
| Q1 2017 | -9.41% |
| Q4 2016 | 0.00% |